Novartis AG
Novartis AG (NVS) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NVS · as of Jun 8, 2026
Key Statistics
Explore Novartis AG Data
nvs stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 25 · Buy rate: 24.0%
The NVS analyst consensus is Hold, based on ratings from 25 Wall Street analysts over the past 3 months. The average 12-month price target is $141.00, representing -5.47% downside from the current price of $149.16.
Competitors & Peers
nvs competitorsNVS
ABBV
AZN
BAYRY
BMY
GILDStock Performance
Full HistoryAbout Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment …
what is novartis ag · nvs stock overview · novartis ag company profile · who is novartis ag ceo · nvs NYSE · novartis ag headquarters · novartis ag business segments
About Stock Overview & Key Data
Novartis AG (NVS) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE since Nov 7, 1996. As of the latest trading session, NVS stock price is $149.16, with a market capitalization of $284.6B. The stock has returned +26.39% over the past 12 months and +8.19% year-to-date.
According to 25 Wall Street analysts, the consensus rating for Novartis AG stock is Hold, with an average 12-month price target of $141.00. In fiscal year 2025, Novartis AG reported revenue of $54.8B and net income of $14.1B. For detailed data — including Novartis AG revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Novartis AG (NVS) stock price is $149.16. The stock is traded on NYSE under the ticker symbol NVS. The 52-week range is $112.34 – $170.46.